Results of Neoteam: A randomized multicenter phase II study of liposomal doxorubicin hydrochloride plus trastuzumab vs conventional doxorubicin both in combination with cyclophosphamide and followed by docetaxel plus trastuzumab as neoadjuvant treatment of HER2-positive primary breast cancer

被引：0
|
作者：
Pernas Simon, S. [1 ]
Rezai, M. [2 ]
Hauschild, M. [3 ]
Machiels, J. P. [4 ]
Paepke, S. [5 ]
Llombart Cussac, A. [6 ]
机构：
[1] Inst Catala Oncol, Dept Oncol, Barcelona, Spain
[2] Luis Hosp, Dept Obstet & Gynaecol, European Breast Ctr, Dusseldorf Med Ctr, Dusseldorf, Germany
[3] Frauenklin, Dept Obstet & Gynaecol, Rheinfelden, Switzerland
[4] Clin Univ St Luc, Dept Oncol, Brussels, Belgium
[5] Sankt Gertrauden Krankenhaus, Dept Breast Surg, Berlin, Germany
[6] IDIBELL, Inst Catala Oncol, Dept Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.72
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Results of clinical endpoints of a randomized phase It trial with doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer
    Schneeweiss, A.
    Ruiz, A.
    Rovira, P.
    Bottini, A.
    Manikhas, A.
    Wacker, J.
    Schumacher, T.
    Wolf, M.
    Segui, M.
    Sinn, P.
    Kennedy, L.
    Mansouri, K.
    Bauknecht, T.
    [J]. BREAST, 2009, 18 : S63 - S63
  • [32] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [33] Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Giermek, J.
    Martin, M.
    Jasiowka, M.
    Mackey, J. R.
    Chan, A.
    Liu, M-C
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T. A.
    Bensfia, S.
    Hitler, S.
    Xu, N.
    Bee-Munteanu, V.
    Drevot, P.
    Press, M. F.
    Crown, J.
    [J]. CANCER RESEARCH, 2016, 76
  • [34] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [35] A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study).
    Masuda, N.
    Toi, M.
    Ueno, T.
    Aogi, K.
    Iwata, H.
    Ohno, S.
    Kuroi, K.
    Sato, N.
    Nakamura, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
    Slamon, D.
    Eiermann, W.
    Robert, N.
    Pienkowski, T.
    Martin, M.
    Rolski, J.
    Chan, A.
    Mackey, J.
    Liu, M.
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T.
    Olsen, S.
    Buyse, M.
    Kiskartalyi, T.
    Landreau, V
    Wilson, V
    Press, M.
    Crown, J.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 500S - 500S
  • [37] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [38] Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer.
    Gavila, J.
    Llombart, A.
    Guerrero, A.
    Ruiz, A.
    Guillem, V.
    [J]. CANCER RESEARCH, 2012, 72
  • [39] Interim Results of BACH: Randomized Phase II Trial Evaluating the Safety of Two Chemotherapy Regimens as Adjuvant Therapy in Patients with HER2-Positive Breast Cancer: PLD plus Cyclophosphamide plus Trastuzumab (PLD plus C plus H), or Doxorubicin plus Cyclophosphomide (A plus C), Each Followed by Paclitaxel plus Trastuzumab (T plus H)
    Rayson, D.
    Suter, T.
    van der Vegt, S.
    Jackisch, C.
    Lluch, A.
    van den Bosch, J.
    Vivanco, Lopez G.
    Van Gent, Mathilde A.
    Wildiers, H.
    Provencher, L.
    Stopatschinskaja, S.
    Srinivasan, S.
    Richel, D.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 620S - 620S
  • [40] Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin/cyclophosphamide followed by taxanes with full-course trastuzumab/pertuzumab for HER2-positive breast cancer: a single-arm, phase II study
    Yang, Yaping
    Jin, Liang
    Li, Yudong
    Gan, Fengxia
    Rao, Nanyan
    Zhang, Jun
    Feng, Ruifa
    Liu, Zhenzhen
    Liu, Qiang
    [J]. CANCER RESEARCH, 2024, 84 (09)
12345